VA
PRAX icon

VR Adviser’s Praxis Precision Medicines PRAX Stock Holding History

VR Adviser’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-989,985
Closed -$37.5M – 36
2025
Q1 		$37.5M Hold
989,985
– – 3.19% 10
2024
Q4 		$76.2M Buy
989,985
+283,854
+40% +$20.5M 5.23% 4
2024
Q3 		$40.6M Hold
706,131
– – 2.13% 17
2024
Q2 		$29.2M Buy
706,131
+5
+0% +$236 1.86% 18
2024
Q1 		$43.1M Buy
706,126
+352,500
+100% +$15.8M 2.05% 17
2023
Q4 		$7.88M Sell
353,626
-1
-0% -$18 0.54% 29
2023
Q3 		$9.07M Hold
353,627
– – 0.95% 26
2023
Q2 		$6.1M Buy
+353,627
New +$5.41M 0.98% 23

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser's PRAX Position: Q2 2025 in Review

VR Adviser sold out of Praxis Precision Medicines (PRAX) in Q2 2025, closing a stake of 989,985 shares — an estimated $37.5M sold.

VR Adviser first reported a position in PRAX in Q2 2023 and held it in 8 quarters. The position peaked at $76.2M in Q4 2024. 143 funds tracked by Wall St. Rank hold PRAX as of Q2 2025.

  • VR Adviser reported no remaining Praxis Precision Medicines position as of Q2 2025 after selling out during the quarter.
  • VR Adviser sold 989,985 Praxis Precision Medicines shares in Q2 2025, an estimated $37.5M.
  • VR Adviser first reported a position in Praxis Precision Medicines in Q2 2023 and held it in 8 quarters.
  • VR Adviser's Praxis Precision Medicines position peaked at $76.2M in Q4 2024.
  • 143 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2025.

Based on VR Adviser's 13F filing for Q2 2025, filed 14 Aug 2025.